Gene expression profiling identifies C/EBPδ as a candidate regulator of endotoxin-induced disseminated intravascular coagulation

American Journal of Respiratory and Critical Care Medicine

Volumn 176, Issue 6, 2007, Pages 602-609

  Slofstra, Sjoukje H ^a,c   Groot, Angelique P ^a   Obdeijn, Maartje H P ^a   Reitsma, Pieter H ^a   Ten Cate, Hugo ^b   Spek, C Arnold ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Endotoxemia; Ischemia reperfusion; Microarray; Transcription factor

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN DELTA; CD14 ANTIGEN; CREATININE; ENDOTOXIN; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; INFECTION; INFLAMMATION; INJURY; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY ISCHEMIA; MORTALITY; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; SEPSIS; SHWARTZMAN PHENOMENON; SYSTEMIC DISEASE; WILD TYPE;

ANIMALS; CCAAT-ENHANCER-BINDING PROTEIN-DELTA; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DISSEMINATED INTRAVASCULAR COAGULATION; ENDOTOXINS; GENE EXPRESSION; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG; MICE; MICE, INBRED C57BL; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX;

EID: 34548626023     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200609-1250OC     Document Type: Article

References (49)

1. Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341:586-592.
2. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, et al. Caring for the critically ill patient: high-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869-1878.
3. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003;290:238-247.
4. Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebocontrolled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996;24:1431-1440.
5. Opal S, Laterre PF, Abraham E, Francois B, Wittebole X, Lowry S, Dhainaut JF, Warren B, Dugernier T, Lopez A, et al. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, doubleblind, placebo-controlled, clinical trial. Crit Care Med 2004;32:332-341.
6. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001;276:11199-11203.
7. Slofstra SH, van't Veer C, Buurman WA, Reitsma PH, ten Cate H, Spek CA. Low molecular weight heparin attenuates multiple organ failure in a murine model of disseminated intravascular coagulation. Crit Care Med 2005;33:1365-1370.
8. Slofstra SH, Ten Cate H, Spek CA. Signal transduction induced by activated protein C: no role in protection against sepsis? Trends Mol Med 2006;12:374-381.
9. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
10. Dhainaut JF, Marin N, Mignon A, Vinsonneau C. Hepatic response to sepsis: interaction between coagulation and inflammatory processes. Crit Care Med 2001;29:S42-S47.
11. Cerra FB. Hypermetabolism, organ failure, and metabolic support. Surgery 1987;101:1-14.
12. Baue AE. Multiple, progressive, or sequential systems failure: a syndrome of the 1970s. Arch Surg 1975;110:779-781.
13. Pine RW, Wertz MJ, Lennard ES, Dellinger EP, Carrico CJ, Minshew BH. Determinants of organ malfunction or death in patients with intra-abdominal sepsis: a discriminant analysis. Arch Surg 1983;118:242-249.
14. Slofstra SH, Ten Cate H, Spek CA. Low dose endotoxin priming is accountable for coagulation abnormalities and organ damage observed in the Shwartzman reaction: a comparison between a single-dose endotoxemia model and a double-hit endotoxin-induced Shwartzman reaction. Thromb J 2006;4:13.
15. Brozna JP. Shwartzman reaction. Semin Thromb Hemost 1990;16:326-332.
16. Garrison RN, Spain DA, Wilson MA, Keelen PA, Harris PD. Microvascular changes explain the "two-hit" theory of multiple organ failure. Ann Surg 1998;227:851-860.
17. Slofstra SH, Spek CA, ten Cate H. Disseminated intravascular coagulation. Hematol J 2003;4:295-302.
18. Slofstra SH, Groot AP, Reitsma PH, ten Cate H, Spek CA. Microarray analysis points towards C/EBPd as a novel mediator in endotoxininduced DIC. Brit J Haematology 2006;133(Suppl 1):31-32.
19. Archer L. Pathologic manifestations of septic shock. In: Proctor RA, editor. Handbook of endotoxin. Amsterdam, Elsevier Science; 1986. pp. 18-54.
20. Leemans JC, Stokman G, Claessen N, Rouschop KM, Teske GJ, Kirschning CJ, Akira S, van der Poll T, Weening JJ, Florquin S. Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J Clin Invest 2005;115:2894-2903.
21. Poli V. The role of C/EBP isoforms in the control of inflammatory and native immunity functions. J Biol Chem 1998;273:29279-29282.
22. Takahashi H, Tashiro T, Miyazaki M, Kobayashi M, Pollard RB, Suzuki F. An essential role of macrophage inflammatory protein 1alpha/ CCL3 on the expression of host's innate immunities against infectious complications. J Leukoc Biol 2002;72:1190-1197.
23. O'Grady NP, Tropea M, Preas HL II, Reda D, Vandivier RW, Banks SM, Suffredini AF. Detection of macrophage inflammatory protein (MIP)-1alpha and MIP-1beta during experimental endotoxemia and human sepsis. J Infect Dis 1999;179:136-141.
24. Hermans PW, Hazelzet JA. Plasminogen activator inhibitor type 1 gene polymorphism and sepsis. Clin Infect Dis 2005;41:S453-S458.
25. Biemond BJ, Levi M, Ten Cate H, Van der Poll T, Buller HR, Hack CE, Ten Cate JW. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci (Lond) 1995;88:587-594.
26. Hack CE, Hart M, van Schijndel RJ, Eerenberg AJ, Nuijens JH, Thijs LG, Aarden LA. Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect Immun 1992;60:2835-2842.
27. Landmann R, Zimmerli W, Sansano S, Link S, Hahn A, Glauser MP, Calandra T. Increased circulating soluble CD14 is associated with high mortality in gram-negative septic shock. J Infect Dis 1995;171:639-644.
28. Antal-Szalmas P. Evaluation of CD14 in host defence. Eur J Clin Invest 2000;30:167-179.
29. Hu X, Yee E, Harlan JM, Wong F, Karsan A. Lipopolysaccharide induces the antiapoptotic molecules, A1 and A20, in microvascular endothelial cells. Blood 1998;92:2759-2765.
30. Arvelo MB, Cooper JT, Longo C, Daniel S, Grey ST, Mahiou J, Czismadia E, Abu-Jawdeh G, Ferran C. A20 protects mice from Dgalactosamine/ lipopolysaccharide acute toxic lethal hepatitis. Hepatology 2002;35:535-543.
31. Zhou Q, Zhao J, Wiedmer T, Sims PJ. Normal hemostasis but defective hematopoietic response to growth factors in mice deficient in phospholipid scramblase 1. Blood 2002;99:4030-4038.
32. Duriez C, Moyret-Lalle C, Falette N, El-Ghissassi F, Puisieux A. BTG2, its family and its tutor. Bull Cancer 2004;91:E242-E253.
33. Boiko AD, Porteous S, Razorenova OV, Krivokrysenko VI, Williams BR, Gudkov AV. A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. Genes Dev 2006;20:236-252.
34. Bradley JR, Pober JS. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 2001;20:6482-6491.
35. Kanamori M, Suzuki H, Saito R, Muramatsu M, Hayashizaki Y. T2BP, a novel TRAF2 binding protein, can activate NF-kappaB and AP-1 without TNF stimulation. Biochem Biophys Res Commun 2002;290:1108-1113.
36. Collazo CM, Yap GS, Sempowski GD, Lusby KC, Tessarollo L, Woude GF, Sher A, Taylor GA. Inactivation of LRG-47 and IRG-47 reveals a family of interferon gamma-inducible genes with essential, pathogen-specific roles in resistance to infection. J Exp Med 2001;194:181-188.
37. Natsuka S, Akira S, Nishio Y, Hashimoto S, Sugita T, Isshiki H, Kishimoto T. Macrophage differentiation-specific expression of NFIL6, a transcription factor for interleukin-6. Blood 1992;79:460-466.
38. Hu HM, Tian Q, Baer M, Spooner CJ, Williams SC, Johnson PF, Schwartz RC. The C/EBP bZIP domain can mediate lipopolysaccharide induction of the proinflammatory cytokines interleukin-6 and monocyte chemoattractant protein-1. J Biol Chem 2000;275:16373-16381.
39. Beck GC, Rafat N, Brinkkoetter P, Hanusch C, Schulte J, Haak M, van Ackern K, van der Woude FJ, Yard BA. Heterogeneity in lipopolysaccharide responsiveness of endothelial cells identified by gene expression profiling: role of transcription factors. Clin Exp Immunol 2006;143:523-533.
40. Thomas B, Berenbaum F, Humbert L, Bian H, Bereziat G, Crofford L, Olivier JL. Critical role of C/EBPdelta and C/EBPbeta factors in the stimulation of the cyclooxygenase-2 gene transcription by interleukin-1beta in articular chondrocytes. Eur J Biochem 2000;267:6798-6809.
41. Thangaraju M, Rudelius M, Bierie B, Raffeld M, Sharan S, Hennighausen L, Huang AM, Sterneck E. C/EBPdelta is a crucial regulator of proapoptotic gene expression during mammary gland involution. Development 2005;132:4675-4685.
42. Sterneck E, Paylor R, Jackson-Lewis V, Libbey M, Przedborski S, Tessarollo L, Crawley JN, Johnson PF. Selectively enhanced contextual fear conditioning in mice lacking the transcriptional regulator CCAAT/enhancer binding protein delta. Proc Natl Acad Sci USA 1998;95:10908-10913.
43. Ratajczak T, Williams PM, DiLorenzo D, Ringold GM. Multiple elements within the glucocorticoid regulatory unit of the rat alpha 1-acid glycoprotein gene are recognition sites for C/EBP. J Biol Chem 1992;267:11111-11119.
44. Kawamura N, Singer L, Wetsel RA, Colten HR. Cis- and trans-acting elements required for constitutive and cytokine-regulated expression of the mouse complement C3 gene. Biochem J 1992;283:705-712.
45. Ochrietor JD, Harrison KA, Zahedi K, Mortensen RF. Role of STAT3 and C/EBP in cytokine-dependent expression of the mouse serum amyloid P-component (SAP) and C-reactive protein (CRP) genes. Cytokine 2000;12:888-899.
46. Huang JH, Liao WS. Induction of the mouse serum amyloid A3 gene by cytokines requires both C/EBP family proteins and a novel constitutive nuclear factor. Mol Cell Biol 1994;14:4475-4484.
47. Taylor FB Jr. Staging of the pathophysiologic responses of the primate microvasculature to Escherichia coli and endotoxin: examination of the elements of the compensated response and their links to the corresponding uncompensated lethal variants. Crit Care Med 2001;29(Suppl 1):S78-S89.
48. Schoenmakers SH, Versteeg HH, Groot AP, Reitsma PH, Spek CA. Tissue factor haploinsufficiency during endotoxin induced coagulation and inflammation in mice. J Thromb Haemost 2004;2:2185-2193.
49. Mahidhara R, Billiar TR. Apoptosis in sepsis. Crit Care Med 2000;28:N105-N113.